Status:
COMPLETED
NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD
Lead Sponsor:
Imperial College London
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
21-70 years
Phase:
NA
Brief Summary
The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in ex...
Detailed Description
Nitric oxide (NO) is produced by resident and inflammatory cells in the respiratory tract by the enzyme NO synthase (NOS), which exists in three isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), an...
Eligibility Criteria
Inclusion
- Healthy non-smokers
- Normal spirometry (FEV1 \>90 % predicted; exhaled NO bigger than or equal to 10 ppb; flow 50 ml/s)
- At risk (current smokers)
- Normal spirometry, with or without chronic symptoms (cough, sputum production)
- FEV1 reversibility of \<15% after inhaled beta2-agonists\*
- Moderate COPD
- FEV1 greater than or equal to 30% and \< 80%
- FEV1/FVC \< 70% predicted
- FEV1 reversibility of \<15% after inhaled beta2-agonists
- With or without chronic symptoms (cough, sputum production, dyspnea)
- Able to comprehend and grant a written informed consent
Exclusion
- Concomitant use or pre-treatment within the last 4 weeks with oral steroids
- Respiratory infection within 4 weeks prior to entry into the trial
- Females who are pregnant or lactating
- History of current or past drug or alcohol abuse
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00180635
Start Date
October 1 2003
End Date
July 1 2006
Last Update
July 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY